HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory Twitter Goes '#Rogue' With AltFDA

This article was originally published in The Rose Sheet

Executive Summary

Underground Twitter feed for FDA starts slow compared to fellow agencies.

You may also be interested in...



FDA Commissioner Candidate Gulfo Hates Breakthrough, Wants To Reevaluate User Fees

In an interview, Joseph Gulfo, former medtech industry CEO and vocal FDA critic, outlines his worldview and interest in pushing aggressively against increasing the FDA ‘body of law.’

A Burning FDA Hiring Freeze Question: What About User Fee-Supported Staff?

Industry worries about user fee programs as US FDA could wait weeks before finding out how President Trump's hiring freeze affects it.

‘He Is Very Pro-Vaccine’: Trump Mulls RFK Jr. To Chair Commission On Safety

Kennedy Jr. has been a long-time proponent of the view that vaccines are a cause of neurological diseases like autism, despite scientific research that has debunked those claims.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel